Geneos Wealth Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Geneos Wealth Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-642	Closed	-$84.7K	–	3259
2025 Q1	$84.7K	Buy	642 +532	+484%	+$66.3K	﹤0.01%	1658
2024 Q4	$9.19K	Buy	110 +26	+31%	+$2.14K	﹤0.01%	2079
2024 Q3	$6.15K	Buy	+84	New	+$6.31K	﹤0.01%	2005

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Geneos Wealth Management's ITCI Position: Q2 2025 in Review

Geneos Wealth Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 642 shares — an estimated $84.7K sold.

Geneos Wealth Management first reported a position in ITCI in Q3 2024 and held it in 3 quarters. The position peaked at $84.7K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Geneos Wealth Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Geneos Wealth Management sold 642 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $84.7K.
Geneos Wealth Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2024 and held it in 3 quarters.
Geneos Wealth Management's Intra-Cellular Therapies Inc. position peaked at $84.7K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Geneos Wealth Management's 13F filing for Q2 2025, filed 18 Aug 2025.